{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-158192","form_type":"8-K","ticker":"RNTX","cik":"0001420565","company_name":"Rein Therapeutics, Inc.","filed_at":"2025-07-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.949322+00:00","generated_at":"2026-05-18T06:53:51.524571+00:00","sec_items":["5.03","8.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Rein Therapeutics receives FDA clinical hold on LTI-03 Phase 2 trial; cites insufficient nonclinical safety data","bullets":["FDA placed Phase 2 RENEW trial of LTI-03 on clinical hold on July 8, 2025 via formal letter.","FDA cited no NOAEL and minimal mucus cell hyperplasia in 26-week rat study; requests new inhalation toxicity study.","Company believes existing data supports safety, plans to work with FDA to resolve hold expeditiously.","Board approved bylaw amendment lowering quorum requirement to 40% of shares outstanding."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-158192","json":"https://secwatch.observer/filing/0001193125-25-158192.json","markdown":"https://secwatch.observer/filing/0001193125-25-158192.md","text":"https://secwatch.observer/filing/0001193125-25-158192.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420565/000119312525158192/0001193125-25-158192-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420565/000119312525158192/d83413d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T06:53:51.524571+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"76f5ac5d644e300585472eaac022c8204332354d","claim":"Rein Therapeutics, Inc.: Amended quorum requirement to 40% of outstanding shares entitled to vote at stockholder meetings (effective 2025-07-10).","evidence_excerpt":"On July 10, 2025, the Board of Directors (the “Board”) of Rein Therapeutics, Inc. (the “Company”) approved an amendment to the Company’s Amended and Restated By-laws (as amended, the “By-laws”), effective immediately, to provide that forty percent (40%) of the shares of capital stock of the Company issued and outstanding and entitled to vote at the meeting, present in person, present by means of remote communication in a manner, if any, authorized by the Board in its sole discretion, or represented by proxy shall constitute a quorum at all meetings of the stockholders for the transaction of business except as otherwise provided by law, the Restated Certificate of Incorporation, as amended, or the By-laws.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1420565/000119312525158192/0001193125-25-158192-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2025-07-10"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}